Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?

In the recently published guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for chronic obstructive pulmonary disease (COPD), the staging system included a Stage 0 for subjects without airways obstruction but with respiratory symptoms, denoting these subjects "at risk" for COPD. Our aim was to validate this staging approach using data from three surveys in The Copenhagen City Heart Study, in which a sample of the general population was examined at baseline and in which, after 5 and 15 years, spirometry was performed at all surveys. Criteria for GOLD Stage 0 was fulfilled by 5.8% of the total adult population and 7.2% of smokers. After 5 and 15 years, 13.2 and 20.5%, respectively, of smokers with GOLD Stage 0 had developed COPD fulfilling criteria for GOLD Stage 1 or worse. This was the case for 11.6 and 18.5%, respectively, of smokers without respiratory symptoms. Further analyses using multivariate logistic regression analysis confirmed that GOLD Stage 0 was not identifying subsequent airways obstruction. When analyzing FEV(1) decline, Stage 0 carried a risk of excess decline. GOLD Stage 0 was not a stable feature, which may explain the lack of predictive value. In the Western world, smoking is still in itself the most important indicator of risk of COPD, and alternative markers of susceptibility in the population must be investigated.

[1]  A. Buist Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[2]  N. Gross The GOLD standard for chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[3]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[4]  E. Silverman,et al.  Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[5]  T. Petty,et al.  Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. , 2000, Chest.

[6]  A. Sanna,et al.  Identification of smokers susceptible to development of chronic airflow limitation: a 13-year follow-up. , 1998, Chest.

[7]  Denmark,et al.  Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study , 2002 .

[8]  P. Sly,et al.  Allergic respiratory disease: strategic targets for primary prevention during childhood. , 1997, Thorax.

[9]  J. Vestbo,et al.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.

[10]  B. Celli Pulmonary rehabilitation in patients with COPD. , 1995, American journal of respiratory and critical care medicine.

[11]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[12]  P. Schnohr,et al.  Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. , 1991, The European respiratory journal.

[13]  P. Schnohr,et al.  Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. , 1990, Thorax.

[14]  A. Buist,et al.  Does the single-breath N2 test identify the smoker who will develop chronic airflow limitation? , 1988, The American review of respiratory disease.

[15]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[16]  B. Bake,et al.  The single breath N2-test predicts the rate of decline in FEV1. The study of men born in 1913 and 1923. , 1986, European journal of respiratory diseases.

[17]  G. Little,et al.  The natural history of chronic bronchitis and emphysema , 1979 .